The primary endpointtime to first tolerated solid mealwas 25.3 hours with ipamorelin versus 32.6 hours with placebo, but this difference did not reach statistical significance (p = 0.15)
Studies have shown that ATP synthase activity and ATP level were reduced in the brains of AD patients [34, 35]
doi:10.1001/jama.2013.280490
Taken together, these points underscore FDAs view that compounded GLP1 products present concrete patient-safety and supplychain risks that warrant heightened scrutiny
Working in a similar way to GHRP-6 or GHRP-2, Ipamorelin keeps the gains lean, since increased appetite is not a side effect of use
Tikka A, Soronen J, Laurila PP, Metso J, Ehnholm C, Jauhiainen M